MIAMI--(BUSINESS WIRE)--TissueTech Inc. announced today that it has been awarded four patents by the U.S. Patent Trademark Office. Two of the patents cover methods of promoting bone formation and the others cover methods for lyophilizing and sterilizing placental tissue.
“TissueTech continues to maintain its status as the leader in the scientific understanding and innovative application of placental tissue in regenerative medicine,” said Amy Tseng, Chief Executive Officer of TissueTech. “In addition to being the recipient of four new patents, the company recently surpassed the milestone of 300,000 human implants performed by clinicians and our research is backed by more than 30 years of continuous funding through the National Institute of Health. The recognition of this technology and its use in medicine underscores our success in finding new and important arenas where regenerative therapy offers the potential to address underserved and unmet clinical needs and improve patients’ lives.”
The four patents issued to TissueTech apply to:
- The use of placental tissue in different forms to address the typical effects of bone diseases including arthritis, osteoporosis, bone tumors, Paget’s Disease, and alveolar bone degradation.
- A method of promoting or inducing osteogenesis in an individual in need thereof, comprising contacting a bone or joint in the individual with a therapeutically-effective amount of placental tissue.
- The preservation and sterilization of placental tissue necessary to make it available to physicians for transplantation to patients in clinical need.
- A method of preparing a placental tissue powder product by lyophilizing placental tissue and grinding the lyophilized tissue to generate a product that can be delivered less invasively.
”TissueTech was the first company to introduce cryopreserved umbilical cord and amniotic membrane tissues for clinical transplantation,” said Scheffer Tseng, MD, Ph.D., Chief Technology Officer of TissueTech. “As a pioneer in this space and with the continued support of our NIH grant and the private capital that we have raised, we will continue to lead in the development of innovative technologies and delivery techniques to better serve patients across all sectors of healthcare with regenerative therapy options.”
Numerous disease states are the direct result of damage to normal tissue and the associated inflammation, along with the body’s consequent inability to restore a normal state of function. Research has demonstrated that regenerative healing occurs in the fetal environment due to the inherent ability of the placental tissues, particularly the umbilical cord and amniotic membrane, to modulate inflammation and create an environment that is conducive to healing. More importantly, these properties can be preserved and transplanted to other environments to facilitate the improved outcomes following surgical procedures or even the closure of chronic, hard-to-heal wounds.
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical and Bio-Tissue, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products. Amniox Medical markets products for use in the musculoskeletal and wound care markets; Bio-Tissue markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 30 continuous years of research grants. Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.